Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics will present six abstracts at the 2026 ASCO Annual Meeting in Chicago, starting May 29. The presentations cover clinical progress for its lead programs: EIK1001 (TLR7/8 dual agonist) in NSCLC and melanoma, EIK1003 (PARP1 inhibitor) in solid tumors, and EIK1005 (WRN inhibitor) in early development.
Key figures
- Drug Name
- EIK1001, EIK1003, EIK1005
- Phase Of Trial
- Phase 1/2, Phase 2/3
- Conference
- ASCO 2026
- Abstract count
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.